. 67:3217-3225, 1993). A molecular genetic approach using EBV recombinants was undertaken to evaluate the role of these transcripts in primary B-lymphocyte growth transformation and latent infection. Since the se transcripts arise from a 22-kbp segment of the EBV genome and construction of large deletion mutants is an improbable result after transfection of infected cells with an EBV DNA fragment with a large deletion mutation, a new approach was taken to make a recombinant with the DNA encoding all of the BARFO RNAs deleted. The approach derives from a recently described strategy for making recombinants from five overlapping EBV cosmid-cloned DNAs (B. Tomkinson, E. Robertson, R. Yalamanchili, R. Longnecker, and E. Kieff, J. Virol. 67:7298-7306, 1993). A large segment of EBV DNA was deleted from the transfected cosmid DNAs by omitting a cosmid which included all of the DNA encoding the BARFO RNA and by ligating the distal halves of the two flanking cosmids so as to create one cosmid which had ends that overlapped with the other two unaltered cosmids. EBV recombinants with 58 kbp including BARFO deleted resulted from transfecting the three overlapping EBV DNA fragments into P3HR-1 cells and simultaneously inducing lytic replication of the endogenous, transformation-defective, P3HR-1 EBV. The endogenous P3HR-1 EBV provided lytic infection and packaging functions. EBV recombinants with intact transforming functions were then selected by infecting primary B lymphocytes and growing the resultant transformed cells in lymphoblastoid cell lines. The efficiency of incorporation of the deletion into transforming EBV recombinants was close to that of a known indifferent marker, the type 1 EBNA 3A gene, indicating the absence of significant selection against the deletion. Cells infected with the deleted recombinant grew similarly to those infected with wild-type recombinants and had a similar level of permissiveness for lytic EBV infection. Thus, the BARFO transcript is not critical to primary B-lymphocyte growth transformation or to latent infection. This methodology is useful for constructing EBV recombinants which are specifically mutated at other sites in the three cosmids and is a step toward deriving a minimal transforming EBV genome.
Epstein-Barr virus (EBV) was discovered over 25 years ago in the search for an infectious etiology for African Burkitt's lymphoma (BL). The virus was soon also associated with nasopharyngeal carcinoma (NPC) (16, 52) . Although the etiologic relationship between EBV and BL or NPC is more complicated than initially envisaged, the virus can rapidly and efficiently induce unrestrained proliferation of human B lymphocytes in vitro and in vivo (2, 5, 15, 16, 33-36, 40, 51, 52) . Molecular biologic investigations have described 10 genes encoding a set of six nuclear proteins (EBNAs), two integral membrane proteins (LMPs), and two small RNAs (EBERs), which are transcribed in latently infected and growth-transformed cells and are therefore likely to be mediators of latent infection or cell growth transformation (for a review, see reference 24). Many biochemical and phenotypic activities of these genes have been defined (for a review, see reference 24) . EBV recombinant-based molecular genetic analysis of the role of specific genetic elements in EBV latency and transformation has indicated that EBNA LP, EBNA 2, EBNA 3A, EBNA 3C, and LMP1 are critical to EBV-mediated B-lymphocyte proliferation at the cellular level, whereas EBNA 3B, LMP2, and the EBERs are not (6, 7, 12, 20, (25) (26) (27) (28) (43) (44) (45) (46) (47) (48) .
Previous recombinant EBV-based molecular genetic evaluations of the role of genes known to be expressed during latency do not exclude the possibility that other parts of the genome may contribute as yet unidentified cis-or tranis-acting functions. This possibility became evident with the finding that EBV DNA mapping at 150 to 160 kbp in the B95-8 genome encodes a hitherto unrecognized family of highly spliced and polyadenylated RNAs in human NPC cells and biopsies and in some latently infected B lymphocytes (3, 4, 11, 12, 19, 37, 42) (Fig. 1) . The abundance of the RNAs decreases with the transition to lytic infection, consistent with a role for the RNAs in latency (19) . One role could be as a final checkpoint in preventing lytic reactivation from latency since the RNAs are antisense (19, 42) to several immediate-early or early lytic infection RNAs (for a review of lytic infection gene expression, see references 9 and 24). Alternatively, the RNAs may encode a protein since they include at their 3' end a short BamA DNA fragment-encoded open reading frame (ORF), which has been given the acronym BARFO, consistent with the usual terminology for EBV ORFs (12) . Some EBV-infected humans have antibody to in vitro-translated BARFO polypeptides (12 9 kbp after the deletion. The primers used for PCR analysis are also indicated (Pr).
BARFO ORF and selecting for recombinants, using a marker rescue of transformation strategy which should have yielded a 10% frequency of recovery of BARFO deletion mutants (45) (46) (47) (48) . None of the recombinants that were obtained had incorporated the BARFO deletion. The failure to obtain the BARFO deletion recombinant could not be adequately explained by a putative stringent requirement for a BARFO-encoded RNA or protein since the experiments were done under conditions in which approximately 50% of the infected primary B lymphocytes are coinfected with P3HR-1 EBV which should be competent for BARFO expression (45) (46) (47) (48) . The failure is more likely due to a low efficiency of recombination caused by the proximity of the BARFO deletion to a 12-kbp deletion, which is a unique characteristic of the transfected B95-8 strain-derived EBV DNA fragment and not a characteristic of the P3HR-1 EBV genome with which it had to recombine (37, 48) (Fig. 1) .
Of the several strategies that have been developed for specifically altering the EBV genome (6, 7, 13, 20, 22, 23, 25-31, 43-48, 50) , the most efficient is through transfection of P3HR-1 cells with five, cosmid-cloned, overlapping DNA fragments representative of the complete B95-8 EBV genome (37, 48) . The efficiency of this strategy derives from the relative ease of transfecting P3HR-1 cells with large EBV DNA fragments, the inducible permissivity of P3HR-1 cells for EBV replication, and the presence in P3HR-1 cells of an endogenous EBV genome which is competent for lytic EBV replication but has a DNA segment encoding part of EBNA LP and EBNA 2 deleted (6, 7, 13, 14, 17, 18, 29, 33, 38, 41, (43) (44) (45) (46) (47) (48) (Fig. 1) , was thereby incorporated into 10% of the resulting recombinant genomes (48) .
The successful incorporation of the B95-8 deletion into 10% of the transforming recombinants in the five cosmid transfections opened the possibility that a substantially larger deletion could be similarly incorporated into EBV recombinants as long as virion "head-full" packaging constraints were not violated. We therefore undertook to make EBV recombinants with deletions of the DNA encoding the entire family of BARFOrelated RNAs. Such experiments could also be a step toward deriving a minimal transforming EBV genome.
MATERIALS AND METHODS
Plasmid and cosmid DNAs. The ESN cosmid was derived by ligating the EcoRI-NotI fragment (residue 95,239 to 117,609) of EcoRI to the NotI-SnaBI fragment (residue 163,415 to 14,294) of SnaBI B and to a modified pDVcosA2 (1, 21, 48 ). The ligated DNA was then packaged into lambda phage and used to infect Escherichia coli PLK-A (Stratagene). pSVNaeI Z was used for induction of lytic EBV infection (8) . The EcoRI A fragment, Sall EC cosmid DNA, and pDVcosA2 were previously described (1, 21, (45) (46) (47) (48) .
Cell cultures. B95-8 is a marmoset LCL immortalized with a Ti EBV (32, 34) . The HH514-16 subclone of P3HR-1 (a gift from George Miller, Yale University, New Haven, Conn.) is infected with the T2 P3HR-1 EBV (17, 33) . The Akata cell line is an EBV-positive group I BL cell line, and the BJAB cell line is an EBV-negative BL cell line (48) . Cells were maintained in complete medium consisting of RPMI 1640 supplemented with 10 to 15% inactivated fetal bovine serum, 2 mM glutamine, 10 ,ug of gentamicin per ml, and 50,000 U of penicillin per ml.
Preparation of EBV recombinants. Cosmid DNA was digested with restriction endonucleases to release the EBV DNA. The three cosmid DNAs (20 p.g of each) were mixed with 25 p.g of pSVNaeI Z DNA, precipitated, resuspended in 400 p.l of complete medium, and transfected into 107 P3HR-1 c16 cells in a 0.4-cm-gap cuvette (Bio-Rad) at 200 V and 960 ,uF (45) (46) (47) (48) . The cells were then immediately diluted into 15 ml of complete medium and incubated at 37°C for 6 days.
Infection of primary B lymphocytes. Primary B lymphocytes were prepared and infected with filtered supernatant (0.45-,um-pore-size) from P3HR-1 cells at 6 days after transfection (45) (46) (47) (48) . Human peripheral blood mononuclear cells (107 cells), depleted of T cells by rosetting with 2-aminoethylisothiouronium bromide-treated sheep erythrocytes at 4°C overnight, were incubated with virus at 37°C for 2 h in 5 ml of complete medium. The infected cells were then diluted in 30 ml of complete medium and plated onto two 96-well microtiter plates at a concentration of 5 x 104 cells per well in a final volume of 150 p1I. The plates were then incubated at 37°C in 5% CO2 for 21 days. The cultures were fed with 100 p.1 of complete medium and incubated at 37°C for another 7 days. LCLs were macroscopically visible by 4 weeks and were expanded.
PCR. Primers were made on an Applied Biosystems model 391 synthesizer and corresponded to bp 117,520 to 117,543 and bp 163,595 to 163,578 (1) for amplification across the deletion Indicates incorporation of the transfected TI Sall E/C fragment. "All except 5 of the 213 were also positive for the TI Sall E/C fragment.
Number infected with an ESN deletion recombinant which lacks WT DNA at the deletion site. WT DNA usually indicates P3HR-1 coinfection.
in the ESN cosmid. This oligonucleotide pair was selected by using the primer program version 0.5 (C)1991, Whitehead Institute for Biomedical Research) and amplifies a 261-bp fragment across the deletion mutant DNA but does not amplify a fragment from wild-type (WT) DNA. The primers used for amplification of WT DNA within the deletion correspond to bp 117,520 to 117,543 and bp 117,677 to 117,653 (1) . These primers amplified a 157-bp DNA fragment from both the P3HR-1 and B95-8 genomes. The primers which flank the P3HR-1 deletion amplify a 257-bp DNA fragment (47) (48) . The primers which result in amplification of type-distinctive fragments from EBNA 3A were described previously (39, (45) (46) (47) (48) . The sensitivity of the WT primers was tested by serial dilution of WT LCL DNA in DNA prepared from an EBVnegative cell line, BJAB.
DNA used in PCR was prepared from 105 cells. The cells were resuspended in 100 RI of 0.2% isotonic phosphatebuffered saline and heated at 95°C for 15 min. Proteinase K (1/10 volume of 10 mg/ml) was added, and the cells were incubated for 60 min at 55°C. The proteinase K was then inactivated by incubation at 95°C for 30 min. PCRs used a Perkin-Elmer thermal cycler machine with 5 pL1 of DNA solution and 0.625 U of Taq DNA polymerase (Stratagene) in a 25-,ul reaction. The amplified products were analyzed by electrophoresis in 1% ME-2% Nusieve (wt/vol)-agarose (FMC) gels in 0.5 x TBE buffer (50 mM Tris, 50 mM boric acid, and 0.5 mM disodium EDTA) (pH 8.0). The gels were stained with ethidium bromide and visualized by UV fluorescence.
Immunoblot, Southern blot, and in situ lysis cell gel analyses. EBV proteins were resolved on 8% denaturing polyacrylamide gels and detected by immunoblot with EBV-immune human serum or with S12 monoclonal antibody to EBV LMP1 (gift of D. Thorley (10) . Gel-fractionated DNAs were transferred to an activated nylon membrane (GeneScreen Plus, New England Nuclear) by capillary action overnight. The membranes were then baked in vacuum for 2 h and hybridized with radioactive probes. EBV DNA fragments were labelled with [32P]dCTP (3,000 Ci/ mmol), using the random primer system (Stratagene). Hybridizations were with probes of 2 x 106 to 4 x 106 cpm/ml at 68°C for 12 to WT DNA within the deletion, and by PCR amplifications which detect differences between the TI and T2 EBNA 3 genes of the transfected DNA and P3HR-1 EBV, respectively (39) . Although the BARFO transcript might be essential for latent infection or growth transformation, the experiments could be done under conditions in which about 50% of the primary B lymphocytes are infected with nonrecombinant P3HR-1 EBV (45-48) which would provide WT BARFO RNA and protein in trans. We were, however, concerned that the resulting genome might be too small to be packaged as a unit-length genome and too large to be packaged as a dimer.
A new cosmid (ESN) was constructed from the TI B95-8 cosmid EBV DNA library so as to potentially enlarge the 12-kbp, B95-8-unique deletion to 58 kbp, thereby deleting all of the DNA encoding BARFO RNAs (Fig. 1) . The ESN cosmid was constructed by splicing together the EcoRI-Notl fragment of the EcoRI B cosmid and the NotI-SnaBI fragment of the SnaBI B cosmid (Fig. 1 ). The resulting cosmid had deletions of the right half of EcoRI B, all of the Sall EBV DNA fragment, and the left half of the SnaBI B cosmid. By deleting nucleotides 117,609 to 163,415 (1), the incorporation of the resulting ESN cosmid into an EBV genome would delete 58 kbp, including the entire BARFO transcript which maps at nucleotides 150,640 to 160,991 (42) . Transfection along with two other cosmids, EcoRI A and Sall E/C, might enable transforming EBV genomes to be generated by recombination among the cosmids. This might even be more efficient than recombination among five cosmids, since with pseudorabies virus, four cosmids containing the entire genome were more efficient than five cosmids in reconstituting the genome after transfection into cells permissive for pseudorabies virus replication (49) . The three cosmids would have a lytic and a latent infection DNA replication origin, the genes for the essential EBNAs and LMPs, and the cis-acting packaging signal (Fig. 1) 16 representative LCLs which were infected only with recombinants which had incorporated the ESN deletion ( Fig. 2A) . All 16 LCLs lacked P3HR-1 DNA, as demonstrated by amplification of a 257-bp fragment from P3HR-1 cells but not from the LCLs, using primers which flank the sites at which EBNALPand EBNA2-encoding DNA are deleted from P3HR-1 (Fig. 1,  shaded area, and Fig. 2B ).
Using primers (EBV bp 117,520 to 117,543 and bp 117,677 to 117,653) specific for WT DNA within the 58-kbp deletion J. VIROL. (bp 117,609 to 163,415; Fig. 1 ), a 157-bp DNA fragment was readily amplified from P3HR-1 and from B95-8 cell DNA but not from any of the 16 recombinant genomes or the ESN cosmid (Fig. 3B ). This primer pair was then used as the basis for a sensitive PCR which would detect as little as one WT EBV genome in 104 cells. Five of the clones shown in Fig. 2 were analyzed in parallel and no WT DNA was detected, excluding any possibility that WT DNA could be contributing to the ability of the EBV genome in these cells to maintain latent infection or cell proliferation. Of the 213 clones which were infected with an EBV recombinant which had the ESN deletion, 89 of 213 or 42% had no detectable WT DNA at this site. Since this is similar to the frequency of P3HR-1 coinfection of WT recombinants in similar experiments (44) (45) (46) (47) (48) (49) , there is no apparent selection for P3HR-1 coinfection which could provide WT BARFO.
Each of the 981 LCLs was also analyzed by PCR with primers which amplify a 276-bp fragment from the Ti EBNA 3A gene and a 237-bp fragment from the T2 EBNA 3A gene (39) . The representative LCLs, which have only the ESN deletion DNA as shown in Fig. 2 , are each infected with EBV with only Ti EBNA 3A DNA, as demonstrated by amplification of only the 276-bp fragment. In contrast, a 237-bp fragment did amplify from the P3HR-1 T2 EBNA 3A gene (Fig. 3A) . This result indicates that these EBV genomes contain Ti SalI E/C DNA from the transfected cosmid and do not contain T2 P3HR-1 EBNA 3A DNA, as would be expected if they had resulted from recombination with the endogenous Southern blot analyses of the EBV genome in LCLs infected with recombinants that lack 58 kbp of EBV DNA by PCR analysis. The structures of the EBV genomes in LCLs which were infected with ESN recombinants were further cvaluated by in situ lysis and restriction endonuclease analyses. By in situ lysis, the EBV genomes in most LCLs were similar in size to those of B95-8 or Akata cell episomes (Fig. 4, lanes IA, 3A , SA, and 6A). Other LCLs had episomes which were significantly smaller (Fig. 4, lanes 2A and 4A) . These (Fig. SA) , EcoRl (Fig. 6A) , and Sall (Fig. 7A) EBV DNA fragments and did not hybridize to any fragmcnt of EBV DNA from the ESN recombinant-infected LCLs. Thcsc results qualitatively confirm the absence of WT DNA from the ESN deletion EBV recombinant-infected cells as was shown above with a quantitatively more sensitive PCR. These results also significantly extend the PCR results by demonstrating the absence of all of the putatively deleted 58 kbp of DNA. The readily distinguishable fragments which are affected by the ESN deletion are indicated by their letter designations to the right of the same blots probed with the EBV DNA from the five overlapping cosmid EBV DNAs (Fig. 5B, 6B, and 7B) . Most of the rest of the fragments of the ESN recombinant DNAs were readily identifiable by their correspondence in size to fragments of the B95-8 genome and were demonstrated to be the expected fragment by their hybridization to individual EBV DNA probes made from each of the cosmids (data not shown). As expected, some fragments did not correspond to fragments of the B95-8 genome and were the result of fusion of two fragments as a result of the ESN deletion. Other fragments which differed from the expected B95-8 EBV DNA fragments were the result of amplification or contraction of an internal or terminal repeat in the ESN deletion recombinant EBV DNA. An example of an amplification of the terminal repeat DNA is the larger than expected Bal-nHI and Sall fragments of EBV DNA in the IA and 3A LCLs (Fig. SB and 7B, asterisks) . An example of a contraction in repeat number is the smaller than expected EcoRI A fragmcnts in the 2A and 4A EBV DNAs (Fig. 6B, dots) . The new fragments created by the ESN deletion are a new Ban HI fragment, approximately the same size as BaniHI E and therefore difficult to distinguish in the blot shown in Fig. SB ; a new EcoRI fragment not well resolved from EcoRI A (Fig. 61B) ; and a new Sall fragment which includes the terminal rcpecat and therefore varies in size and is evident at approximately 9.5 kbp (Fig. 7B) . All fragments in the blots probed with a single EBV DNA cosmid clone corresponded to the fragments expected, cxcept for the frag- ments that were produced by the terminal repeats and the large IR1 repeats which appear to undergo contractions and expansions within the recombinant genomes.
Expression of EBNAs, LMP1, and lytic infection-associated (Fig. 8A) . Further, each cell line had the Ti EBNA 2, EBNA 3A, EBNA 3B, and EBNA 3C (Fig. 8A) .
Moreover, the level of expression of EBNA LP, EBNA 2, EBNA 1, EBNA 3A, EBNA 3B, and EBNA 3C (Fig. 8A ) was similar to that in B95-8 cells. The size and level of LMP1 expression was also similar to that in B95-8 cells (Fig. 8B) (Fig. 9) . The size of the Z protein was similar to that of B95-8 and slightly larger than that of P3HR-I (Fig. 9B) . The abundance of the 45-to 55-kDa BMRFI and BMLF1 early lytic infection proteins correlated with the abundance of Z (Fig.  9A ). (20, (43) (44) (45) (46) (47) (48) .
An obvious deficiency of the system is that recombinants carrying null mutations in essential latency, transforming, or replicative genes cannot be obtained or reactivated to lytic infection and the progeny passaged in primary B lymphocytes without coinfection with the P3HR-1 EBV genome. The ESN recombinants have deletions of an EBV DNA segment from bp 117,609 to 163,415. This segment includes the BARFO gene and a large number of genes which are normally expressed immediate early, early, or late in lytic EBV infection (for reviews, see references 9 and 24). These include the BALF2 gene, which encodes the single-stranded DNA binding protein; the BALF3 gene, which may encode a glycoprotein transport protein; BALF4, which encodes gpl1 0; BALF5, which encodes the EBV DNA polymerase; BI'LF4, which encodes an immediate-early transactivator; BILF2, which encodes a glycoprotein; BGLF5, which encodes an alkaline DNase; BGLF4, which encodes a protein kinase; and BXLF2, which encodes gp85. Thus, lytic EBV replication is aborted in the LCLs infected with the ESN recombinants alone.
One objective of these experiments was to investigate the role of the BARFO RNA in latent infection and cell growth transformation. This family of rightward RNAs which appear to initiate at EBV genome coordinate 150,640 (42) was first identified in NPC tumor biopsies and in NPC tumor cells passaged in nude mice (3, 4, 11, 12, 19, 42) . NPC is a common J. VIROL. < < < < < :. Cy) o, .-e\j en Rcr Ln n-cn < malignancy in some human populations, and almost all anaplastic NPCs are latently infected with EBV. The BARFO RNAs, EBNA I RNA, and LMP1 and LMP2 RNAs are commonly detected in NPC tumors and have also been found in some latently infected B lymphocytes (3, 4, 19, 42) . Although our data demonstrate that the BARFO RNA is not critical for latent EBV infection of B-lymphocytes or cell growth transformation in vitro, BARFO-encoded protein is expressed in vivo (12) and may be important for epithelial or lymphocyte infection in vivo. The BARFO RNA is also antisense to an immediate-early and several early lytic replication-associated genes and could serve as a "last stopper" for the transition to lytic infection (19, 42) . The deletion recombinants that are described in this report cannot encode the sense as well as the antisense transcripts through this region and therefore do not directly test whether the BARFO RNA counters a putative effect of the opposite-strand transcripts in enhancing the transition to lytic infection. However, the major immediateearly transactivators of lytic EBV infection, Z and R, are not expected to be affected by the deletion or by the BARFO RNAs (for a review, see reference 24), and Z expression was similar to that in WT LCLs.
Further experiments are in progress with the goal of deleting other parts of the EBV genome to more precisely define the minimal transforming genome. It is likely that the ESN deletion can be extended to the EBNA 1 and LMPI RNA termination sites and that much of the DNA between the terminal repeat and the long internal repeat can be deleted. In fact, the EBNA 3B (46), LMP2 (25) (26) , EBER (44), BHRFI (23, 31) , and BCRFI genes (43) and the BamC latency promoter (43) are not critical for lymphocyte infection or cell growth transformation in vitro. Deletion of most of the rest of the genome could have an adverse effect on processing of the EBNA mRNAs which are essential for episome maintenance or cell growth transformation.
